Analyzing plaque types in coronary artery disease using advanced imaging and immune profiling
Official title: Single-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease - a Prospective, Observational Study
Run by Harbin Medical University · NCT06489119 · Data updated 2026-11-12
This study is testing how different types of plaque in the arteries affect heart disease by using advanced imaging and immune cell analysis to help improve patient care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 350 (estimated) |
| Sponsor | Harbin Medical University Academic / other |
| Locations | 2 sites (Harbin, Heilongjiang and 1 other locations) |
| Status | Recruiting |
| Started | July 7, 2024 |
| Main results expected | January 15, 2026 |
| Study ends | July 15, 2026 |
| Registry record updated | September 15, 2025 |
| Trial ID | NCT06489119 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 to 85 with varying degrees of coronary artery stenosis, particularly those with stable, vulnerable, or ruptured plaques.
✕Probably not a fit
Patients with coronary angiographic diameter stenosis less than 30% may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The MOOP-CAD program investigates the progression of coronary atherosclerotic plaques by integrating in vivo imaging techniques, specifically optical coherence tomography (OCT), with single-cell multi-omics analysis of circulating immune cells. This observational study aims to correlate the imaging characteristics of coronary plaques with their molecular and immune profiles, providing insights into the pathophysiological processes involved in coronary artery disease. By examining different plaque subtypes, the study seeks to enhance understanding of plaque behavior and its implications for patient management.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for patients with coronary artery disease.
How similar studies have gone: While this approach is innovative, similar studies utilizing multi-omics in cardiovascular research have shown promising results, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female, Age ≥ 18 years and ≤ 85 years. 2. Ability to understand the requirements of the study and to provide informed consent. Control group: Patients with coronary angiographic diameter stenosis \<20%. Stable plaque group: 1. Have been clinically stable for at least 6 months. 2. Presence of ≥1 lesion with angiographic diameter stenosis \>50% with no TCFA lesions in the most severely narrowed native coronary artery (target vessel). TCFA was defined as a lipidic plaque with the thinnest FCT \<75 mm and maximum lipid arc \>180°. 3. Rule out elevation of troponin or myocardial enzymology. Vulnerable plaque group: 1. Have been clinically stable for at least 6 months. 2. Presence of ≥1 lesion with angiographic diameter stenosis \>50% with TCFA lesions in the most severely narrowed native coronary artery (target vessel). 3. Rule out elevation of troponin or myocardial enzymology. Plaque rupture group: 1. Persistent chest pain for 30 minutes, arrival at the hospital within 24 hours from symptom onset. ST-segment elevation of \>0.1 mV in ≥2 contiguous leads or new-onset left bundle branch block, and high sensitive Troponin T or I or CK/CK-MB above upper reference value. 2. Exist clearly identified culprit lesion. 3. Plaque rupture was defined by the presence of a discontinuity of the fibrous cap with a cavity formed inside the plaque. Plaque erosion group: 1. Persistent chest pain for 30 minutes, arrival at the hospital within 24 hours from symptom onset. ST-segment elevation of \>0.1 mV in ≥2 contiguous leads or new-onset left bundle branch block, and high sensitive Troponin T or I or CK/CK-MB above upper reference value. 2. Exist clearly identified culprit lesion. 3. Plaque erosion was defined by the presence of the attached thrombus overlying the intact fibrous cap of the atherosclerotic plaque, luminal surface irregularity at the culprit lesion in the absence of thrombus, or attenuation of the underlying plaque by thrombus without superficial lipid or calcium at the site of the thrombus. Exclusion Criteria: 1. Cardiogenic shock or circulatory depression,life-threatening arrhythmia. 2. Known systolic heart failure with LVEF ≤30%. 3. Severe systemic diseases (end-stage renal disease, serious liver dysfunction, chronic active inflammatory diseases, active oncologic diseases, autoimmune diseases). 4. Septicemia, acute inflammatory event with fever. 5. Patients with organ transplants or patients on the waiting list for an organ transplant. 6. Previous CABG treatment, PCI treatment of the target vessel, and PCI treatment of non-target vessels within 1 year. 7. Thrombolysis before PCI. 8. Stenosis of the left main artery ≥50%. 9. Characteristics rendering high-quality OCT imaging unlikely such as chronic total occlusion, pronounced tortuosity, heavily calcified vessels. 10. Infarcted vessel with a diameter \>4mm or \<2.5mm. 11. "No-reflow" (TIMI 0-1) after thrombus aspiration or predilatation. 12. Other subjects deemed unsuitable for study by investigators.
Where it's running
-
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China Recruiting -
China-Japan Union Hospital of Jilin
Changchun, Jilin, China Recruiting
Study contacts
- Study coordinator: Bo Yu, MD,PhD
- Email: yubodr@163.com
- Phone: 86-045186605180
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
-
Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance
This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.
-
Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in CABG Patients
This study tests whether the amount a patient’s pulse pressure varies during surgery relates to how quickly lactate levels drop after CABG.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.